{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:21:22Z","timestamp":1791231682358,"version":"4.1.0"},"reference-count":92,"publisher":"American Psychiatric Association Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2000,1,1]]},"DOI":"10.1176\/ajp.157.1.4","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T09:22:50Z","timestamp":1424337770000},"page":"4-15","source":"Crossref","is-referenced-by-count":297,"title":["Cholinesterase Inhibitors: A New Class of Psychotropic Compounds"],"prefix":"10.1176","volume":"157","author":[{"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1571CHDHCCHJ","doi-asserted-by":"crossref","unstructured":"Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS (the Tacrine Collaborative Study Group): A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer\u2019s disease. N Engl J Med 1992; 327:1253\u20131259","DOI":"10.1056\/NEJM199210293271801"},{"key":"R1571CHDJJFAE","doi-asserted-by":"crossref","unstructured":"Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J (Tacrine Study Group): A controlled trial of tacrine in Alzheimer\u2019s disease. JAMA 1992; 268:2523\u20132529","DOI":"10.1001\/jama.268.18.2523"},{"key":"R1571CHDGACCA","doi-asserted-by":"crossref","unstructured":"Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (Tacrine Study Group): A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease. JAMA 1994; 271:985\u2013994","DOI":"10.1001\/jama.1994.03510370037029"},{"key":"R1571CHDIBIAD","doi-asserted-by":"crossref","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (Donepezil Study Group): A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Neurology 1998; 50:136\u2013145","DOI":"10.1212\/WNL.50.1.136"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT (Donepezil Study Group): Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158:1021\u20131031","DOI":"10.1001\/archinte.158.9.1021"},{"key":"R1571CHDCADAG","doi-asserted-by":"crossref","unstructured":"Rogers SL, Friedhoff LT (Donepezil Study Group): The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293\u2013303","DOI":"10.1159\/000106895"},{"key":"R1571CHDGEEIG","doi-asserted-by":"crossref","unstructured":"Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B (Metrifonate Study Group): Metrifonate treatment of the cognitive deficits of Alzheimer\u2019s disease. Neurology 1998; 50:1214\u20131221","DOI":"10.1212\/WNL.50.5.1214"},{"key":"R1571CHDDFCIJ","doi-asserted-by":"crossref","unstructured":"Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer\u2019s disease. Neurology 1998; 50:1222\u20131230","DOI":"10.1212\/WNL.50.5.1222"},{"key":"R1571CHDIGGJD","unstructured":"Corey-Bloom J, Anand R, Veach J (ENA 713 B352 Study Group): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer\u2019s disease. Int J Geriatr Psychopharmacol 1998; 1:55\u201365"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR: Safety\/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer\u2019s disease. Life Sci 1996; 58:1201\u20131207","DOI":"10.1016\/0024-3205(96)00081-1"},{"key":"R1571CHDEIGDH","doi-asserted-by":"crossref","unstructured":"Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin H, Hartmann R, Gharabawi M: B303 Exelon study group: efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. Br Med J 1999; 318:633\u2013640","DOI":"10.1136\/bmj.318.7184.633"},{"key":"R1571CHDIJGFD","doi-asserted-by":"crossref","unstructured":"Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD: A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer\u2019s disease. Neurology 1999; 52:1146\u20131152","DOI":"10.1212\/WNL.52.6.1146"},{"key":"R1571CHDHIECH","doi-asserted-by":"crossref","unstructured":"Imbimbo BP, Lucca U, Lucchelli F, Alberoni M, Thal LJ (Eptastigmine Study Group): A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer\u2019s disease. Alzheimer Dis Assoc Disord 1998; 12:313\u2013322","DOI":"10.1097\/00002093-199812000-00011"},{"key":"R1571CHDJDCCG","doi-asserted-by":"crossref","unstructured":"Rainer M: Galantamine in Alzheimer\u2019s disease: a new alternative to tacrine? CNS Drugs 1997; 2:89\u201397","DOI":"10.2165\/00023210-199707020-00001"},{"key":"R1571CHDIFBEG","doi-asserted-by":"crossref","unstructured":"Antuono PG (Mentane Study Group): Effectiveness and safety of velnacrine for the treatment of Alzheimer\u2019s disease: a double-blind, placebo-controlled study. Arch Intern Med 1995; 155:1766\u20131772","DOI":"10.1001\/archinte.155.16.1766"},{"key":"R1571CHDGBJAA","doi-asserted-by":"crossref","unstructured":"Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry 1984; 141:1356\u20131364","DOI":"10.1176\/ajp.141.11.1356"},{"key":"R1571CHDDCEGJ","doi-asserted-by":"crossref","unstructured":"Folstein MF, Folstein SE, McHugh PR: \u201cMini-Mental State\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189\u2013198","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"R1571CHDIIADE","doi-asserted-by":"crossref","unstructured":"Knopman DS, Knapp MJ, Gracon SI, Davis CS: The Clinician Interview-Based Impression (CIBI): a clinician\u2019s global change rating scale in Alzheimer\u2019s disease. Neurology 1994; 44:2315\u20132321","DOI":"10.1212\/WNL.44.12.2315"},{"key":"R1571CHDJFGEE","doi-asserted-by":"crossref","unstructured":"Cummings JL, Kaufer D: Neuropsychiatric aspects of Alzheimer\u2019s disease: the cholinergic hypothesis revisited. Neurology 1996; 47:876\u2013883","DOI":"10.1212\/WNL.47.4.876"},{"key":"R1571CHDHJAEA","doi-asserted-by":"crossref","unstructured":"Schegg KM, Harrington LS, Nielsen S, Zwieg RM, Peacock JH: Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer\u2019s disease. Neurobiol Aging 1992; 13:697\u2013704","DOI":"10.1016\/0197-4580(92)90092-C"},{"key":"R1571CHDCHDAF","doi-asserted-by":"crossref","unstructured":"Younkin SG, Goodridge B, Katz J, Lockett G, Nafziger D, Usiak MF, Younkin LH: Molecular forms of acetylcholinesterase in Alzheimer\u2019s disease. Fed Proc 1986; 45:2982\u20132988","DOI":"10.1097\/00005072-198605000-00190"},{"key":"R1571CHDJICBH","doi-asserted-by":"crossref","unstructured":"Xiang Z, Huguenard JR, Prince DA: Cholinergic switching within neocortical inhibitory networks. Science 1998; 281:985\u2013988","DOI":"10.1126\/science.281.5379.985"},{"key":"R1571CHDGBFGF","doi-asserted-by":"crossref","unstructured":"Mesulam M-M, Mufson EJ: Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. Brain 1984; 107:253\u2013274","DOI":"10.1093\/brain\/107.1.253"},{"key":"R1571CHDGJAFG","doi-asserted-by":"crossref","unstructured":"Flynn DD, Ferrari-DiLeo G, Mash DC, Levery AL: Differential regulation of modular subtypes of muscarinic receptors in Alzheimer\u2019s disease. J Neurochem 1995; 64:1888\u20131891","DOI":"10.1046\/j.1471-4159.1995.64041888.x"},{"key":"R1571CHDFHBDA","doi-asserted-by":"crossref","unstructured":"Zhou H-X, Wlodek ST, McCammon JA: Conformation gating as a mechanism for enzyme specificity. Proc Natl Acad Sci USA 1998; 95:9280\u20139283","DOI":"10.1073\/pnas.95.16.9280"},{"key":"R1571CHDBHHJJ","doi-asserted-by":"crossref","unstructured":"Fishman EB, Siek GC, MacCallum RD, Bird ED, Volicer L, Marquis JK: Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol 1986; 19:246\u2013252","DOI":"10.1002\/ana.410190305"},{"key":"R1571CHDCIJFA","doi-asserted-by":"crossref","unstructured":"Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer\u2019s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10:122\u2013126","DOI":"10.1002\/ana.410100203"},{"key":"R1571CHDEGDBI","doi-asserted-by":"crossref","unstructured":"Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT: Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215:1237\u20131239","DOI":"10.1126\/science.7058341"},{"key":"R1571CHDJFBFF","doi-asserted-by":"crossref","unstructured":"Rasool CG, Svendsen CN, Selkoe DJ: Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer\u2019s disease. Ann Neurol 1986; 20:482\u2013488","DOI":"10.1002\/ana.410200407"},{"key":"R1571CHDGBHBH","doi-asserted-by":"crossref","unstructured":"Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A: Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer\u2019s disease. Synapse 1997; 26:341\u2013350","DOI":"10.1002\/(SICI)1098-2396(199708)26:4<341::AID-SYN2>3.0.CO;2-6"},{"key":"R1571CHDHFFDH","doi-asserted-by":"crossref","unstructured":"Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, Candy JM, Edwardson JA, Fairbairn A: Cholinergic receptors in cognitive disorders. Can J Neurol Sci 1986; 13:521\u2013527","DOI":"10.1017\/S0317167100037240"},{"key":"R1571CHDEFJDH","doi-asserted-by":"crossref","unstructured":"Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ (Eptastigmine Study Group): Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer\u2019s disease. Neurology 1999; 52:700\u2013708","DOI":"10.1212\/WNL.52.4.700"},{"key":"R1571CHDIHAAG","doi-asserted-by":"crossref","unstructured":"Harrell LE, Calloway R, Morere D, Falgout J: The effect of long-term physostigmine administration in Alzheimer\u2019s disease. Neurology 1990; 40:1350\u20131354","DOI":"10.1212\/WNL.40.9.1350"},{"key":"R1571CHDEJCEH","doi-asserted-by":"crossref","unstructured":"Shader RI, Harmatz JS, Salzman C: A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment\u2014Geriatric (SCAG). J Am Geriatr Soc 1974; 22:107\u2013113","DOI":"10.1111\/j.1532-5415.1974.tb01521.x"},{"key":"R1571CHDHCIID","doi-asserted-by":"crossref","unstructured":"Schwartz AS, Kohlstaedt EV: Physostigmine effects in Alzheimer\u2019s disease: relationship to dementia severity. Life Sci 1986; 38:1021\u20131028","DOI":"10.1016\/0024-3205(86)90236-5"},{"key":"R1571CHDIGJDF","doi-asserted-by":"crossref","unstructured":"Wirkowski E, Prohovnik I, Young WL: Observations on the physostigmine syndrome in patients with Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci 1991; 3:73\u201375","DOI":"10.1176\/jnp.3.1.73"},{"key":"R1571CHDDGEBE","doi-asserted-by":"crossref","unstructured":"Molchan SE, Vitiello B, Minichiello M, Sunderland T: Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer\u2019s disease (letter). Arch Gen Psychiatry 1991; 48:1113","DOI":"10.1001\/archpsyc.1991.01810360077011"},{"key":"R1571CHDGFHDC","doi-asserted-by":"crossref","unstructured":"Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer\u2019s disease. Biol Psychiatry 1993; 33:536\u2013541","DOI":"10.1016\/0006-3223(93)90009-3"},{"key":"R1571CHDDHHJC","unstructured":"Gorman DG, Read S, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer\u2019s disease. Neuropsychiatry Neuropsychol Behav Neurol 1993; 6:229\u2013234"},{"key":"R1571CHDGHGBB","doi-asserted-by":"crossref","unstructured":"Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M (Dementia Trialists\u2019 Collaboration): Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA 1998; 280:1777\u20131782","DOI":"10.1001\/jama.280.20.1777"},{"key":"R1571CHDIDHHD","doi-asserted-by":"crossref","unstructured":"Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB: Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer\u2019s disease. Arch Neurol 1997; 54:836\u2013840","DOI":"10.1001\/archneur.1997.00550190026010"},{"key":"R1571CHDDABBI","doi-asserted-by":"crossref","unstructured":"Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer\u2019s disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9:1\u20136","DOI":"10.1177\/089198879600900101"},{"key":"R1571CHDFAIED","doi-asserted-by":"crossref","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308\u20132314","DOI":"10.1212\/WNL.44.12.2308"},{"key":"R1571CHDDAGDD","doi-asserted-by":"crossref","unstructured":"Kaufer D, Cummings JL, Christine D: Differential neuropsychiatric symptom responses to tacrine in Alzheimer\u2019s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10:55\u201363","DOI":"10.1176\/jnp.10.1.55"},{"key":"R1571CHDHABEJ","doi-asserted-by":"crossref","unstructured":"Raskin A, Crook T: Relative\u2019s Assessment of Global Symptomatology (RAGS). Psychopharmacol Bull 1988; 24:759\u2013763","DOI":"10.1016\/0014-3057(88)90012-2"},{"key":"R1571CHDHBGFD","doi-asserted-by":"crossref","unstructured":"Small G, Donohue J, Brooks R: An economic evaluation of donepezil in the treatment of Alzheimer\u2019s disease. Clin Ther 1998; 20:838\u2013850","DOI":"10.1016\/S0149-2918(98)80145-8"},{"key":"R1571CHDEGJBB","doi-asserted-by":"crossref","unstructured":"Shea C, MacKnight C, Rockwood K: Aspects of dementia: donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10:229\u2013238","DOI":"10.1017\/S1041610298005341"},{"key":"R1571CHDHGGEG","doi-asserted-by":"crossref","unstructured":"Perry EK, Kerwin J, Perry RH, Irving D, Blessed G, Fairbairn A: Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1990; 1:2\u20134","DOI":"10.1159\/000107114"},{"key":"R1571CHDBBDBH","doi-asserted-by":"crossref","unstructured":"Aarsland D, Bronnick K, Karlsen K: Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999; 14:69\u201372","DOI":"10.1002\/(SICI)1099-1166(199901)14:1<69::AID-GPS888>3.0.CO;2-C"},{"key":"R1571CHDDJHBB","doi-asserted-by":"crossref","unstructured":"Kaufer DI, Catt KE, Lopez OL, DeKosky ST: Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998; 51:1512","DOI":"10.1212\/WNL.51.5.1512"},{"key":"R1571CHDBAADH","unstructured":"Cummings JL, Cyrus PA, Ruzicka BB, Gulanski B: The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer\u2019s disease patients (abstract). Neurology 1999; 524:4"},{"key":"R1571CHDJHCEG","doi-asserted-by":"crossref","unstructured":"Raskind M, Cyrus PA, Ruzicka BB, Gulanski B: Metrifonate Study Group: the effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer\u2019s disease patients. J Clin Psychiatry 1999; 60:318\u2013325","DOI":"10.4088\/JCP.v60n0510"},{"key":"R1571CHDFFEHH","doi-asserted-by":"crossref","unstructured":"Becker R, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V, Markwell S, Moriearty P, Parks R, Shillcutt S, Unni L, Vicari S, Womack C, Zec R: Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990; 19:425\u2013434","DOI":"10.1002\/ddr.430190407"},{"key":"R1571CHDIFEEA","doi-asserted-by":"crossref","unstructured":"Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S: Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer\u2019s disease. Alzheimer Dis Assoc Disorder 1996; 10:124\u2013131","DOI":"10.1097\/00002093-199601030-00003"},{"key":"R1571CHDHBCII","doi-asserted-by":"crossref","unstructured":"Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799\u2013812","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"R1571CHDEIGGC","doi-asserted-by":"crossref","unstructured":"Spagnoli A, Lucca U, Menasce G: Long-term acetyl-L-carnitine treatment in Alzheimer\u2019s disease. Neurology 1991; 41:1726\u20131732","DOI":"10.1212\/WNL.41.11.1726"},{"key":"R1571CHDGEAAG","unstructured":"Jan G, McKeith IG: Special workshop in dementia with Lewy bodies (abstract). Neurobiol Aging 1998; 19:45"},{"key":"R1571CHDIIBJH","doi-asserted-by":"crossref","unstructured":"Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA III, Murphy DL: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Arch Gen Psychiatry 1987; 44:418\u2013426","DOI":"10.1001\/archpsyc.1987.01800170032006"},{"key":"R1571CHDHHHAE","unstructured":"Gershon S, Olariu J: JB 329\u2014a new psychotomimetic, its antagonism by tetrahydroaminoacridine and its comparison with LSD, mescaline and serynl. J Neuropsychiatry 1960; 1:283\u2013292"},{"key":"R1571CHDDFIIC","doi-asserted-by":"crossref","unstructured":"Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1996; 61:324\u2013325","DOI":"10.1136\/jnnp.61.3.324-a"},{"key":"R1571CHDHDFJI","doi-asserted-by":"crossref","unstructured":"Zweig RM, Schegg K, Peacock JH, Melarkey D: A case of Alzheimer\u2019s disease and hippocampal sclerosis with normal cholinergic activity in basal forebrain, neocortex, and hippocampus. Neurology 1989; 39:288\u2013290","DOI":"10.1212\/WNL.39.2.288"},{"key":"R1571CHDEDIJF","doi-asserted-by":"crossref","unstructured":"Whitehouse PJ, Hedreen JC, White CL III, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13:243\u2013248","DOI":"10.1002\/ana.410130304"},{"key":"R1571CHDGJEAE","doi-asserted-by":"crossref","unstructured":"Davis K, Mohs R, Marin D, Purohit D, Perl D, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281:1401\u20131406","DOI":"10.1001\/jama.281.15.1401"},{"key":"R1571CHDBGAGB","doi-asserted-by":"crossref","unstructured":"Poirier J, Delisle M-C, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer\u2019s disease. Proc Natl Acad Sci USA 1995; 92:12260\u201312264","DOI":"10.1073\/pnas.92.26.12260"},{"key":"R1571CHDGJCFE","doi-asserted-by":"crossref","unstructured":"Allen SJ, MacGowan SH, Tyler S, Wilcock GK, Robertson AGS, Holden PH, Smith SKF, Dawbarn D: Reduced cholinergic function in normal and Alzheimer\u2019s disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 1997; 239:33\u201336","DOI":"10.1016\/S0304-3940(97)00872-0"},{"key":"R1571CHDJJAEJ","doi-asserted-by":"crossref","unstructured":"Salehi A, Gonzalez Martinez V, Swaab DF: A sex difference and no effect of ApoE type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer\u2019s disease. Neurobiol Aging 1998; 19:505\u2013510","DOI":"10.1016\/S0197-4580(98)00106-7"},{"key":"R1571CHDFEHBF","doi-asserted-by":"crossref","unstructured":"Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer\u2019s disease. Neurology 1998; 50:669\u2013677","DOI":"10.1212\/WNL.50.3.669"},{"key":"R1571CHDGFDAA","doi-asserted-by":"crossref","unstructured":"Schneider LS, Farlow MR, Henderson VW, Pogoda JM: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer\u2019s disease. Neurology 1996; 46:1580\u20131584","DOI":"10.1212\/WNL.46.6.1580"},{"key":"R1571CHDBGGAC","doi-asserted-by":"crossref","unstructured":"Decker MW, McGaugh JL: The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991; 7:151\u2013168","DOI":"10.1002\/syn.890070209"},{"key":"R1571CHDDHHHG","doi-asserted-by":"crossref","unstructured":"Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV: Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson\u2019s disease. Brain 1992; 115:1701\u20131725","DOI":"10.1093\/brain\/115.6.1701"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Dubois B, Pillon B, Lhermitte F, Agid Y: Cholinergic deficiency and frontal dysfunction in Parkinson\u2019s disease. Ann Neurol 1990; 28:117\u2013121","DOI":"10.1002\/ana.410280202"},{"key":"R1571CHDDAEEE","doi-asserted-by":"crossref","unstructured":"Van Spaendonck KP, Berger HJ, Horstink MW, Buytenhuijs EL, Cools AR: Impaired cognitive shifting in parkinsonian patients on anticholinergic therapy. Neuropsychologia 1993; 31:407\u2013411","DOI":"10.1016\/0028-3932(93)90164-U"},{"key":"R1571CHDDHCCG","doi-asserted-by":"crossref","unstructured":"Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky ST: Assessing the impact of neuropsychiatric symptoms in Alzheimer\u2019s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998; 46:210\u2013215","DOI":"10.1111\/j.1532-5415.1998.tb02542.x"},{"key":"R1571CHDIGBBI","doi-asserted-by":"crossref","unstructured":"Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer\u2019s disease. Am J Psychiatry 1990; 147:1049\u20131051","DOI":"10.1176\/ajp.147.8.1049"},{"key":"R1571CHDFCFJG","doi-asserted-by":"crossref","unstructured":"Uhl GR, Hilt DC, Hedreen JC, Whitehouse PJ, Price DL: Pick\u2019s disease (lobar sclerosis): depletion of neurons in the nucleus basalis of Meynert. Neurology 1983; 33:1470\u20131473","DOI":"10.1212\/WNL.33.11.1470"},{"key":"R1571CHDCGGBD","doi-asserted-by":"crossref","unstructured":"Tagliavini F, Pilleri G: Neuronal loss in the basal nucleus of Meynert in a patient with olivopontocerebellar atrophy. Acta Neuropathol 1985; 66:127\u2013133","DOI":"10.1007\/BF00688687"},{"key":"R1571CHDBEEFD","doi-asserted-by":"crossref","unstructured":"Tagliavini F, Pilleri G, Gemignani F, Lechi A: Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol 1983; 61:157\u2013160","DOI":"10.1007\/BF00697397"},{"key":"R1571CHDCJBHC","doi-asserted-by":"crossref","unstructured":"Nakano I, Hirano A: Neuron loss in the nucleus basalis of Meynert in parkinsonism-dementia complex of Guam. Ann Neurol 1983; 13:87\u201391","DOI":"10.1002\/ana.410130118"},{"key":"R1571CHDFGFBA","doi-asserted-by":"crossref","unstructured":"Cullen KM, Halliday GM: Mechanisms of cell death in cholinergic basal forebrain neurons in chronic alcoholics. Metab Brain Dis 1995; 10:81\u201391","DOI":"10.1007\/BF01991785"},{"key":"R1571CHDDBDFB","doi-asserted-by":"crossref","unstructured":"Rogers JD, Brogan D, Mirra SS: The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 1985; 17:163\u2013170","DOI":"10.1002\/ana.410170210"},{"key":"R1571CHDIDAHH","doi-asserted-by":"crossref","unstructured":"Cummings JL, Benson DF: The role of the nucleus basalis of Meynert in dementia: review and reconsideration. Alzheimer Dis Assoc Disord 1987; 1:128\u2013145","DOI":"10.1097\/00002093-198701030-00003"},{"key":"R1571CHDBIAAE","doi-asserted-by":"crossref","unstructured":"Murdoch I, Perry EK, Court JA, Graham DI, Dewar D: Cortical cholinergic dysfunction after human head injury. J Neurotrauma 1998; 15:295\u2013305","DOI":"10.1089\/neu.1998.15.295"},{"key":"R1571CHDJCDGB","doi-asserted-by":"crossref","unstructured":"Mendez M, Younesi F, Perryman K: Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999; 11:268\u2013270","DOI":"10.1176\/jnp.11.2.268"},{"key":"R1571CHDFDCBC","doi-asserted-by":"crossref","unstructured":"McGeer PL, McGeer EG, Suzuki J, Dolman CE, Nagai T: Aging, Alzheimer\u2019s disease, and the cholinergic system of the basal forebrain. Neurology 1984; 34:741\u2013745","DOI":"10.1212\/WNL.34.6.741"},{"key":"R1571CHDIBJJH","doi-asserted-by":"crossref","unstructured":"Burt T, Sachs G, Demopulos C: Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1999; 45:959\u2013964","DOI":"10.1016\/S0006-3223(98)00320-5"},{"key":"R1571CHDDEBCG","doi-asserted-by":"crossref","unstructured":"White K, Cummings JL: Schizophrenia and Alzheimer\u2019s disease: clinical and pathophysiologic analogies. Compr Psychiatry 1996; 37:188\u2013195","DOI":"10.1016\/S0010-440X(96)90035-8"},{"key":"R1571CHDCBABE","doi-asserted-by":"crossref","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM: Effects of xanomeline, a selective receptor agonist, on cognitive function and behavioral symptoms in Alzheimer\u2019s disease. Arch Neurol 1997; 4:465\u2013473","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"R1571CHDFBFBF","doi-asserted-by":"crossref","unstructured":"Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingarten H: Multiple-dose arecoline infusions in Alzheimer\u2019s disease. Arch Gen Psychiatry 1988; 45:901\u2013905","DOI":"10.1001\/archpsyc.1988.01800340023003"},{"key":"R1571CHDIIFAB","doi-asserted-by":"crossref","unstructured":"Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM: Intraventricular bethanechol infusion for Alzheimer\u2019s disease: results of double-blind and escalating-dose trials. Neurology 1988; 38:219\u2013222","DOI":"10.1212\/WNL.38.2.219"},{"key":"R1571CHDGBHEF","doi-asserted-by":"crossref","unstructured":"Read SL, Frazee J, Shapira J, Smith C, Cummings JL, Tomiyasu U: Intracerebroventricular bethanechol for Alzheimer\u2019s disease: variable dose-related responses. Arch Neurol 1990; 47:1025\u20131030","DOI":"10.1001\/archneur.1990.00530090105020"},{"key":"R1571CHDEBHEE","doi-asserted-by":"crossref","unstructured":"Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB: Induction of depression with oxotremorine in patients with Alzheimer\u2019s disease. Am J Psychiatry 1987; 144:468\u2013471","DOI":"10.1176\/ajp.144.4.468"},{"key":"R1571CHDIDAGF","doi-asserted-by":"crossref","unstructured":"Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingarten H, Mellow A, Murphy DL: Intravenous nicotine in Alzheimer\u2019s disease: a pilot study. Psychopharmacology (Berl) 1988; 95:171\u2013175","DOI":"10.1007\/BF00174504"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.157.1.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T12:43:56Z","timestamp":1722343436000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.157.1.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1,1]]}},"alternative-id":["10.1176\/ajp.157.1.4"],"URL":"https:\/\/doi.org\/10.1176\/ajp.157.1.4","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1,1]]}}}